The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Swiss ministers met with senior executives from Roche and Novartis to discuss the potential impact of U.S. import tariffs on pharmaceuticals. While pharmaceuticals currently avoid these tariffs, an ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital ...

Novartis (LON:0QLR) (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, ...

Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab ...

Roche (RHHBY) and Novartis (NVS) are scheduled to meet with Swiss officials this week amid U.S. tariff threats on pharma ...

The Swiss government met with executives of Roche Holding AG and Novartis AG to discuss the pharmaceutical industry’s situation in light of US tariffs.

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.